Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LaFleur Advancing Restart of Beacon Gold Mill and Bulk Sample for Swanson Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(1784)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on May 01, 2024 12:11pm
smallcapdiscoveries
https://www.youtube.com/watch?v=Ek0C9XfbYa4 The company discussed is Cipher. Interview with Dakota @LeftField_FHRS Smallcap Discoveries 5.05K subscribers
...more
(11)
•••
SushiGobbler
X
Comment by
SushiGobbler
on May 01, 2024 12:04pm
RE:RE:RE:RE:Cipher Pharmaceuticals Reports Fourth Quarter
People are pricing in their Truclera nail fungus cream future potential sales i believe, which has been predicted to bring in tens/hundreds of millions in revenue annually potentially if all goes well
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 03, 2024 7:06am
New Press Release - Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 3, 2024) - Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.Dates:Tuesday April 16...
read article.
(6289)
•••
retiredcf
X
Post by
retiredcf
on Apr 01, 2024 1:25pm
Volatile Market
Now back down to below where we were after the initial positive reaction to their earnings. Makes little sense other than the stock being firmly in the hands of momentum traders and/or stop losses
...more
(6289)
•••
retiredcf
X
Post by
retiredcf
on Mar 30, 2024 1:27pm
Comparison
Could you please compare and contrast CPH and VHI? Looking for key differences or attributes. Is one better than the other, or if starting a new position, would you just allocate funds 50/50? These
...more
(6289)
•••
retiredcf
X
Post by
retiredcf
on Mar 26, 2024 10:22am
Ryan Irvine
Go to the 17 min of the clip and he will tell you why he selected CPH back in September. It remains his first pick of three; for anyone interested, the other two are DNG and VBNK. GLTA https
...more
(6289)
•••
retiredcf
X
Post by
retiredcf
on Mar 23, 2024 1:06pm
Finally an Assessment
Results yesterday from CPH and DR both looked excellent and the stock prices have moved up significantly in response. They both look cheap, particularly CPH, even more so if you ex out the $2.20 cash
...more
(76)
•••
colourama
X
Comment by
colourama
on Mar 21, 2024 1:53pm
RE:RE:RE:Cipher Pharmaceuticals Reports Fourth Quarter
Absolutely great results by CPH, but am I wrong in thinking this is getting expensive? 20x TTM free cash flow, 14x TTM EBITDA. I don't see where the growth is coming from to support the multiples,
...more
(6289)
•••
retiredcf
X
Comment by
retiredcf
on Mar 20, 2024 2:50pm
RE:RE:RE:Cipher Pharmaceuticals Reports Fourth Quarter
Although I stiil haven't been able to find any analyst coverage, it seems safe to say that judging by the continued strength of the SP together with solid trading volume, they also liked what they
...more
(1)
•••
GJS471
X
Comment by
GJS471
on Mar 15, 2024 4:52pm
RE:RE:Cipher Pharmaceuticals Reports Fourth Quarter
It has been a long and winding road, so to speak, for Cipher. I have always liked the model but not so much the execution and poor stock prices. But I have stuck it out for many
...more
(6289)
•••
retiredcf
X
Post by
retiredcf
on Mar 15, 2024 2:03pm
Analyst Coverage
We'll have to look out for one or more of these to confirm what we believe to be excellent results. GLTA Analyst Coverage
...more
(6289)
•••
retiredcf
X
Comment by
retiredcf
on Mar 15, 2024 1:19pm
RE:Cipher Pharmaceuticals Reports Fourth Quarter
With the SP up close to 13% and closing in on the second highest trading volume day in the past year, it seems safe to conclude that the market is pleased with these results. GLTA
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Mar 14, 2024 5:56pm
Conference Call
Cipher will hold a conference call on March 15, 2024, at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by
...more
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Mar 14, 2024 5:55pm
Cipher Pharmaceuticals Reports Fourth Quarter
(All figures are presented in U.S. Dollars) Cash at December 31, 2023 was $39.8 million (CDN$52.7 million) or $1.66 per outstanding common share (CDN$2.20
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 14, 2024 5:00pm
New Press Release - Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results
(All figures are presented in U.S. Dollars)Cash at December 31, 2023 was $39.8 million (CDN$52.7 million) or $1.66 per outstanding common share (CDN$2.20)Full year adjusted EBITDA of $12.7 million, an increase of 2.2% over fiscal 2022Epuris revenue grew by 10% in Q4 2023 compared to Q4...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Have you held units of a TD mutual fund through a discount broker? Learn more.
ReGen III: Pioneering a Cleaner Lubricants Future with Patented Re-Refining